Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Taro Sakamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5917-7201; OpenAlex author ID A5020931739. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 14

  1. Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a multicenter study. Co-author DOI 10.1007/s00595-026-03416-8↗
  2. Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.21873/cdp.10600↗
  3. The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resection for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002416↗
  4. Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-024-03315-x↗
  5. The prognosis-based classification model in resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2024.102035↗
  6. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101998↗
  7. D1 Distal Pancreatectomy for Left-sided Pancreatic Ductal Adenocarcinoma Is Justifiable: A Propensity-score Matched Multicenter Study. Co-author DOI 10.21873/anticanres.16150↗
  8. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. First author DOI 10.1371/journal.pone.0267623↗
  9. Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001767↗
  10. Incidental abdominal lymph node metastases from a known breast cancer in resected specimen of invasive pancreatic ductal adenocarcinoma: report of a case. Co-author DOI 10.1007/s13691-019-00382-6↗
  11. Combination of Distance from Superior Mesenteric Artery and Serum CA19-9 as a Novel Prediction of Local Recurrence in Patients With Pancreatic Cancer Following… Co-author DOI 10.21873/anticanres.13264↗
  12. Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. Co-author DOI 10.21873/anticanres.12485↗
  13. Preoperative Platelet-to-Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. Co-author DOI 10.21873/anticanres.11378↗
  14. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Co-author DOI 10.1016/j.surg.2015.03.043↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshihiro Shirai · 10 shared papers, 2015–2026 · strength 1.77
  2. Koichiro Haruki · 11 shared papers, 2015–2026 · strength 1.67
  3. Toru Ikegami · 8 shared papers, 2022–2026 · strength 1.65
  4. Takeshi Gocho · 9 shared papers, 2018–2026 · strength 1.63
  5. Shinji Onda · 8 shared papers, 2018–2026 · strength 1.45
  6. Kenei Furukawa · 7 shared papers, 2021–2026 · strength 1.42
  7. Ryoga Hamura · 6 shared papers, 2019–2026 · strength 1.10
  8. Masashi Tsunematsu · 5 shared papers, 2023–2026 · strength 1.05
  9. Norimitsu Okui · 4 shared papers, 2024–2026 · strength 0.95
  10. Yoshiaki Tanji · 4 shared papers, 2023–2026 · strength 0.93
  11. Michinori Matsumoto · 4 shared papers, 2019–2026 · strength 0.75
  12. Tadashi Uwagawa · 5 shared papers, 2018–2024 · strength 0.73
  13. Katsuhiko K. Yanaga · 7 shared papers, 2015–2022 · strength 0.71
  14. Hiroaki Shiba · 6 shared papers, 2015–2022 · strength 0.62
  15. Mitsuru Yanagaki · 3 shared papers, 2023–2025 · strength 0.61
  16. Tomohiko Taniai · 3 shared papers, 2019–2025 · strength 0.51
  17. Yosuke Igarashi · 2 shared papers, 2024–2025 · strength 0.45
  18. Kyohei Abe · 3 shared papers, 2018–2023 · strength 0.40
  19. Hironori Shiozaki · 2 shared papers, 2021–2023 · strength 0.29
  20. Takashi Aida · 1 shared paper, 2026 · strength 0.26
  21. Yuta Yamada · 1 shared paper, 2026 · strength 0.26
  22. Yuki Fujiwara · 3 shared papers, 2015–2019 · strength 0.23
  23. Shuichi Fujioka · 1 shared paper, 2023 · strength 0.16
  24. Takashi Horiuchi · 2 shared papers, 2015–2017 · strength 0.12
  25. Fumitake Suzuki · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.